التفاصيل البيبلوغرافية
| العنوان: |
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study. |
| المؤلفون: |
Roviello, Giandomenico, Gambale, Elisabetta, Giorgione, Roberta, Santini, Daniele, Stellato, Marco, Fornarini, Giuseppe, Rebuzzi, Sara Elena, Basso, Umberto, Bimbatti, Davide, Doni, Laura, Nesi, Gabriella, Bersanelli, Melissa, Buti, Sebastiano, De Giorgi, Ugo, Galli, Luca, Sbrana, Andrea, Conca, Raffaele, Carella, Claudia, Naglieri, Emanuele, Pignata, Sandro |
| المصدر: |
Cancer Medicine; Aug2022, Vol. 11 Issue 16, p3084-3092, 9p |
| مصطلحات موضوعية: |
RENAL cell carcinoma, NIVOLUMAB, WATCHFUL waiting, TREATMENT effectiveness, VASCULAR endothelial growth factor receptors, DISEASE progression |
| مستخلص: |
Background: Nivolumab and cabozantinib are currently approved agents in metastatic renal cell carcinoma (mRCC) but there are no data available for patients progressing to both treatments. The aim of this study was to compare active therapeutic options and best supportive care (BSC) after progression to nivolumab and cabozantinib in mRCC. Methods: In this retrospective study, we selected 50 patients from eight Italian centers. The primary endpoint of the study was the overall survival (OS) of patients on active treatment versus BSC. Secondary endpoints were the progression‐free survival (PFS) and objective response rate (ORR). The efficacy of active therapy was also investigated. Results: After progression to both nivolumab and cabozantinib, 57.1% of patients were given active treatment (mainly everolimus and sorafenib) while 42.9% received BSC. The median OS was 13 months (95% CI: 4‐NR) in actively treated patients and 3 months (95% CI: 2–4) in BSC patients (p = 0.001). Patients treated with sorafenib had better disease control than those treated with everolimus (stable disease: 71.4% vs. 16.7%, progression disease: 14.3% vs. 58.3%; p = 0.03), with no significant differences in PFS (5 and 3 months, 95% CI: 1–6 vs. 2–5; p = 0.6) and OS (12 and 4 months, 95% CI: 3‐NR vs. 2‐NR; p = 0.2). Conclusion: After treatment with both nivolumab and cabozantinib, the choice of a safe active systemic therapy offered better outcomes than BSC. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancer Medicine is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder